Cover Image
市場調查報告書

神經節苷脂的中國市場分析

Investigation Report on China Ganglioside Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333482
出版日期 內容資訊 英文 35 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經節苷脂的中國市場分析 Investigation Report on China Ganglioside Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 35 Pages
簡介

中國的醫藥品市場上,高血壓、高脂肪血、血小板栓塞的治療藥領域游外資型企業獨佔,國內企業雖未持有任何優勢,不過,在血管擴張藥和神經保護劑等領域有獨有性。神經節苷脂也是其中之一,由於以近幾年國內企業的技術開發和推銷活動,各種的神經症 (中風、幼兒腦損傷性麻痺、癡呆症、脊髓損傷等) 的領域急速擴大了市場。2005年是7000億人民幣的市場規模,以44.5%年複合成長率(CAGR) 成長,2014年擴大到17億6000萬人民幣為止。

本報告提供中國的神經節苷脂的市場相關分析、整體市場規模和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、今後的市場趨勢預測等調查評估。

第1章 神經節苷脂的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的神經節苷脂市場概況

  • 中國國內的神經節苷脂專利的申請、認證情形
  • 主要製造商
  • 市場規模

第3章 神經節苷脂銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的神經節苷脂市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的神經節苷脂市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 神經節苷脂的醫院用標準價格

  • TRB Pharma Ind Quimica E Farmaceutica Ltda (巴西)
  • TRB Pharma S.A. (阿根廷) (商標名:SYGEN)
  • Wellso Pharmaceutical (商標名:Aogan)
  • Beijing Science Sun Pharmaceutical Co., Ltd
  • Jilin Yinglian Biopharmaceutical Co., Ltd
  • Qilu Pharmaceutical Co., Ltd (商標名:Shenjie)
  • Southwest Pharmaceutical Co., Ltd
  • Changchun Xiangtong Pharmaceutical Co., Ltd
  • Medical University Pharmaceutical Co., Ltd (商標名:Bosijie)

第7章 中國國內的神經節苷脂的主要製造商

  • Qilu Pharmaceutical Co., Ltd
  • Medical University Pharmaceutical Co., Ltd
  • Beijing Science Sun Pharmaceutical Co., Ltd
  • Changchun Xiangtong Pharmaceutical Co., Ltd
  • Wellso Pharmaceutical

第8章 中國的神經節苷脂市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506224

Cardia-cerebrovascular disease is the first big disease with a mortality rate of 20% in the world and over 40% in China. Besides, as most cardia-cerebrovascular diseases are chronic diseases, long-term treatment is needed, which has forced the big market of cardia-cerebrovascular chemicals. As the major varieties of chemicals for the treatment of hypertension, hyperlipidemia and thrombusare are dominated by foreign enterprises, local enterprises have no advantages. However, there are four domestic varieties in the field of vasodilation drugs and neuronprotective agents, among which ganglioside is included.

Ganglioside preparations first came to market in Italy in the 1980s and were marketed into China by TRB Pharma S.A. and TRB Pharma Ind Quimica E Farmaceutica Ltda under the trade name of SYGEN at the end of 1990s. In Nov. 2004, Qilu Pharmaceutical Co., Ltd became the first approved manufacturer of the active pharmaceutical ingredients (APIs) and injection of ganglioside sodium and power-injection under the trade name of Shenjie later. Currently, there are 7 approved manufacturers of ganglioside sodium in China, among which Qilu Pharmaceutical Co., Ltd, Medical University Pharmaceutical Co., Ltd, Beijing Science Sun Pharmaceutical Co., Ltd, Changchun Xiangtong Pharmaceutical Co., Ltd and Wellso Pharmaceutical take the lion's share.

The marketing of domestic ganglioside injection has improved the breed structure of nervous system drugs and its market share for sales value sales volume has grown fast driven by academic education and product propaganda. For over two years, the wide use of ganglioside injection for the treatment of cerebral apoplexy, child cerebral palsy, dementia and spinal cord injury has further driven the rapid growth of nervous system drugs in hospitals.

According to CRI's market survey, the sales value of ganglioside in China rose from less than CNY 70 million in 2005 to CNY 1.76 billion in 2014, CAGR during this period reaching up to 44.5%. the market size of ganglioside is expected to keep growing in the next few years in China.

Readers can get at least the following information from this report:

  • market size of ganglioside in China
  • competitive landscape of ganglioside in Chinese market
  • price of ganglioside made by different enterprises in China
  • market outlook of ganglioside in China

The author suggests the following groups of people purchase this report:

  • manufacturers of nervous system drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

Table of Contents

1. Related Concepts of Ganglioside

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Ganglioside in China

  • 2.1. Patent and Approval Status of Ganglioside in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Ganglioside in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Ganglioside in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Ganglioside in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Ganglioside in Chinese Hospitals in 2014

  • 6.1. TRB Pharma Ind Quimica E Farmaceutica Ltda (Brazil)
  • 6.2. TRB Pharma S.A. (Argentina) (Trade Name: SYGEN)
  • 6.3. Wellso Pharmaceutical (Trade Name: Aogan)
  • 6.4. Beijing Science Sun Pharmaceutical Co., Ltd

6.5Jilin Yinglian Biopharmaceutical Co., Ltd

  • 6.6. Qilu Pharmaceutical Co., Ltd (Trade Name: Shenjie)
  • 6.7. Southwest Pharmaceutical Co., Ltd
  • 6.8. Changchun Xiangtong Pharmaceutical Co., Ltd
  • 6.9. Medical University Pharmaceutical Co., Ltd (Trade Name: Bosijie)

7. Major Manufacturers of Ganglioside in Chinese Market, 2010-2014

  • 7.1. Qilu Pharmaceutical Co., Ltd
  • 7.2. Medical University Pharmaceutical Co., Ltd
  • 7.3. Beijing Science Sun Pharmaceutical Co., Ltd
  • 7.4. Changchun Xiangtong Pharmaceutical Co., Ltd
  • 7.5. Wellso Pharmaceutical

8. Market Outlook of Ganglioside in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Ganglioside in China
  • Chart Sales Status of Ganglioside in China, 2010-2014
  • Chart Sales Value of Ganglioside in China, 2010-2014
  • Chart Sales Value of Ganglioside in Some Regions in China, 2010-2014
  • Chart Sales Volume of Ganglioside in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Ganglioside for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Ganglioside Made by Qilu Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Ganglioside Made by Medical University Pharmaceutical in China, 2010-2014
  • Chart Sales Value and Market Share of Ganglioside Made by Beijing Science Sun Pharmaceutical in China, 2010-2014
  • Chart Sales Value and Market Share of Ganglioside Made by Changchun Xiangtong in China, 2010-2014
  • Chart Sales Value and Market Share of Ganglioside Made by Wellso Pharmaceutical in China, 2010-2014
  • Chart Price of Ganglioside Made by TRB Pharma Ind Quimica E Farmaceutica Ltda (Brazil) in Some Chinese Cities in 2014
  • Chart Price of Ganglioside Made by TRB Pharma S.A. (Argentina) in Some Chinese Cities in 2014
  • Chart Price of Ganglioside Made by Wellso Pharmaceutical in Some Chinese Cities in 2014
  • Chart Price of Ganglioside Made by Beijing Science Sun Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Ganglioside Made by Jilin Yinglian Biopharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Ganglioside Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top